Stem cell scientists have revealed the origins of a common ovarian cancer by modeling fallopian tube tissues, allowing them to characterize how a genetic mutation puts women at high risk for this cancer. The created tissues, known as organoids, hold potential for predicting which individuals will develop ovarian cancer years or even decades in advance, allowing for early detection and prevention strategies.
While the lifetime risk of developing ovarian cancer is less than 2% for the general female population, the estimated risk for women who carry a mutation in the so-called BRCA-1 gene is between 35% and 70%, according to the American Cancer Society.
Faced with such steep odds, some women with BRCA-1 mutations choose to have their breasts or ovaries and fallopian tubes surgically removed even though they may never develop cancers in these tissues. The new study findings, published in Cell Reports, could help physicians pinpoint which of these women are most likely to develop ovarian cancer in the future—and which are not—and pursue new ways to block the process or treat the cancer.
“We created these fallopian organoids using cells from women with BRCA-1 mutations who had ovarian cancer,” explained Clive Svendsen, PhD, executive director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute in a news release.
The research team generated induced pluripotent stem cells (IPSCs), which can produce any type of cell. They started with blood samples taken from two groups of women: young ovarian cancer patients who had the BRCA-1 mutation and a control group of healthy women. Investigators then used the iPSCs to produce organoids modeling the lining of fallopian tubes and compared the organoids in the two groups.
“We were surprised to find multiple cellular pathologies consistent with cancer development only in the organoids from the BRCA-1 patients,” said Nur Yucer, PhD, project scientist in Svendsen’s lab and first author of the Cell Reports study. “Organoids derived from women with the most aggressive ovarian cancer displayed the most severe organoid pathology.”
Besides showing how ovarian cancer is “seeded” in the fallopian tubes of women with mutated BRCA-1, the organoid technology potentially can be used to determine if a drug might work against the disease in an individual, Svendsen said. Each organoid carries the genes of the person who provided the blood sample, making it a “twin” of that person’s own fallopian tube linings. Multiple drugs can be tested on the organoids without exposing the patient to them.